Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
This is not a financial advice!
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Massive block buys!
We need to break 9.0.
Keep an eye on 13.0 level, needs to get broken for a further upmove. You can take partial profits at this level if u want to lock in gains.
SL under 5.7
TP approx. 15.0
Most info on the chart.
Trade carefully!
This is not a financial advice!
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Massive block buys!
We need to break 9.0.
Keep an eye on 13.0 level, needs to get broken for a further upmove. You can take partial profits at this level if u want to lock in gains.
SL under 5.7
TP approx. 15.0
Most info on the chart.
Trade carefully!
Note
05:30:27PMREPL
Block Trade: REPL 635,800 @ $8.53
Signals
Tuesday March 12, 2024
06:28:24PM
REPL
Block Trade: REPL 911,100 @ $8.70
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.